[HTML][HTML] Relapse after allogeneic stem cell transplantation of acute myelogenous leukemia and myelodysplastic syndrome and the importance of second cellular …
CZ Brambilla, SM Lobaugh, JD Ruiz, PB Dahi… - … and cellular therapy, 2021 - Elsevier
Patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) who
relapse after allogeneic hematopoietic cell transplantation (allo-HCT) generally have poor
overall survival (OS). Interventions that result in improved OS after relapse are not well
established. The efficacy of second cellular therapy and specific indications are matters of
debate. This study was conducted to evaluate factors associated with postrelapse survival
and the efficacy of a second course of cellular therapy. We retrospectively analyzed …
relapse after allogeneic hematopoietic cell transplantation (allo-HCT) generally have poor
overall survival (OS). Interventions that result in improved OS after relapse are not well
established. The efficacy of second cellular therapy and specific indications are matters of
debate. This study was conducted to evaluate factors associated with postrelapse survival
and the efficacy of a second course of cellular therapy. We retrospectively analyzed …